Intellia Therapeutics
NASDAQ: NTLACambridge, US · Founded 2014 · Delaware corporation · 505 employees on LinkedIn · 7 known investors
Find your way into Intellia Therapeutics
1,723 people in our graph share verified history with the Intellia Therapeutics team — schools, employers, funds. One of them is your warm intro.
Dan Lynchunlockedknows Nessan Bermingham · together at Xilio Therapeutics (overlapped)
×5knows the team · via Barclays
knows the team · via Boston College
knows the team · via University of Wisconsin-Madison
knows the team · via Atlas Venture
knows the team · via Pillsbury Winthrop Shaw Pittman LLP
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.
Founders & leadership
Intellia Therapeutics was founded in 2014 by Nessan Bermingham and Jennifer Doudna.
NB
Nessan BerminghaminFounder, President & CEO2014–2017Nessan Bermingham founded Intellia Therapeutics, which achieved IPO within two years of inception, and has held leadership positions at multiple gene editing and RNA therapeutics companies including Korro Bio, Stylus Medicine, Liberate Bio, Excelsior Sciences, and EveryOne Medicines over nearly three decades in life sciences.
JD
Jennifer DoudnaCo-founder
JR
Jose RiverainLegal Consultant2022–2022Jose Rivera is an executive with 20 years of experience in legal and business roles at multinational corporations, including leadership of intellectual property, litigation, regulatory, ethics and compliance functions, with expertise in antitrust, corporate governance, and mergers and acquisitions.
JL
John LeonardinPresident and Chief Executive Officer, Member Board of DirectorsJohn Leonard held the role of Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie before joining Intellia to lead the company's research efforts in developing CRISPR/Cas9 gene editing therapies. He received his M.D. from Johns Hopkins University School of Medicine and completed clinical training in internal medicine at Stanford University School of Medicine and the National Institutes of Health.
JB
James BastainExecutive Vice President, General Counsel and Corporate SecretaryExecutive Vice President, General Counsel and Corporate Secretary at Intellia Therapeutics. Basta brings over 25 years of experience in law firm and in-house counsel roles, with background in business law, corporate governance, securities, M&A, licensing, and compliance.
ED
Edward DulacinExecutive Vice President, Chief Financial OfficerEdward Dulac is Executive Vice President and Chief Financial Officer at Intellia Therapeutics, a clinical-stage biopharmaceutical company developing CRISPR/Cas9 gene editing therapies for genetic diseases. He brings experience in finance, capital raising, business development, and corporate strategy within the biopharmaceutical industry.
BS
Birgit SchultesinExecutive Vice President, Chief Scientific OfficerBirgit Schultes is Executive Vice President and Chief Scientific Officer at Intellia Therapeutics, a clinical-stage biopharmaceutical company developing CRISPR/Cas9 gene editing therapies for genetic diseases. She brings expertise in oncology, immunology, and cell therapeutics including antibodies and T cell-based approaches.
MS
Marika St. AmandinSenior Vice President, Chief Human Resources OfficerSenior Vice President and Chief Human Resources Officer at Intellia Therapeutics, Marika St. Amand brings over two decades of human resources experience in the biotechnology industry, with expertise in organizational scaling, talent management, and employee development.
Board
CG
JF
RH
Rachel HaurwitzinMember of the Board of Directors2014–2016President and Chief Executive Officer, Co-founder at Caribou Biosciences
Investors · 7
Reported raises · per SEC filings
Form D private placements$70M disclosed across 1 of 2 rounds · 2015–2026
▶$70MraisedSep 2015 · 28 investors · BiotechnologyRule 506(b)
▶$70MraisedSep 2015 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nessan BerminghamExecutive Officer, Director
- Jose RiveraExecutive Officer
- Carl GordonDirector
- Jean-Francois FormelaDirector
- John LeonardExecutive Officer, Director
- Rachel HaurwitzDirector
- Offering amount
- $70M
- Amount sold
- $70M
- Sales commissions
- $2.3M
- Placement agents
- Leerink Partners LLC
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$631.7Mvaluation at IPOMay 2016 · $18.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
3 people who came through Intellia Therapeutics went on to found or lead other companies.
Competitors · 2
by search overlapBYJU'S165 shared keywordsBYJU'S offers online learning programs, video lessons, and a personalized learning app for students in India, including tutoring and exam-preparation programs for competitive tests such as JEE and NEET.
Massive Bio139 shared keywordsMassive Bio operates an AI-based platform that matches cancer patients with oncology clinical trials and provides concierge support throughout the trial process. It serves patients across the U.S., Canada, Latin America, and Europe, and works with pharma and CRO customers, patient advocacy organizations, and the National Cancer Institute's network of cancer centers.
Companies competing with Intellia Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Will Narrowing Six‑Month Losses Shape Intellia Therapeutics' (NTLA) Gene‑Editing Investment Narrative? - Simply Wall St Newssimplywall.st · Aug 2026Intellia Therapeutics (NTLA) Stock Rises As Pipeline Progress Lifts Sentiment - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does Intellia Therapeutics do?
- Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.
- Who founded Intellia Therapeutics?
- Intellia Therapeutics was founded by Nessan Bermingham, Jennifer Doudna in 2014.
- Who are Intellia Therapeutics's investors?
- Intellia Therapeutics's investors include age1, Atlas Venture, Avoro Capital Advisors, EcoR1 Capital, Foresite Capital, Fidelity Investments, OrbiMed.
- How much funding has Intellia Therapeutics raised?
- Intellia Therapeutics has disclosed $70M raised across 1 of its 2 known rounds.
- Where is Intellia Therapeutics headquartered?
- Intellia Therapeutics is headquartered in Cambridge, US.